東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Protein Interactors Alter Progestero...

University of Kansas., Cancer Biology.

FindBook

Google Book

Amazon

博客來

Protein Interactors Alter Progesterone Receptor (PR) Transcriptional Programs and Oncogenic Potential in Breast Cancer.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Protein Interactors Alter Progesterone Receptor (PR) Transcriptional Programs and Oncogenic Potential in Breast Cancer./
作者:	Holloran, Sean Matthew.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	126 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-03, Section: B.
Contained By:	Dissertations Abstracts International83-03B.
標題:	Molecular biology. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28644924
ISBN:	9798535575001

Protein Interactors Alter Progesterone Receptor (PR) Transcriptional Programs and Oncogenic Potential in Breast Cancer.
Holloran, Sean Matthew.

Protein Interactors Alter Progesterone Receptor (PR) Transcriptional Programs and Oncogenic Potential in Breast Cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 126 p.

Source: Dissertations Abstracts International, Volume: 83-03, Section: B.

Thesis (Ph.D.)--University of Kansas, 2021.

This item must not be sold to any third party vendors.

Breast cancer is the second leading cause of cancer-related death among women in the United States. Upon diagnosis most breast cancers are diagnosed as hormone receptor (HR) positive. HR-positive tumors are classified by their expression of estrogen receptor (ER) and progesterone receptor (PR). ER signaling has been the primary focus of targeted therapies for HR-positive breast cancer. Standard of care for treatment of HR-positive breast cancer is to target ER/estrogen. Though these treatments have initial efficacy in most women with HR-positive breast cancer, many women will eventually relapse on these therapies. Thus, underscoring the clinical need for new, non-ER/estrogen-based treatments. The study of PR in breast cancer development and progression is not well understood. PR is a ligand-activated nuclear receptor that transcriptionally regulates a large repertoire of genes involved in cell cycle, growth, proliferation, and survival. PR/progesterone regulation has been well studied, but the impacts of other hormones, proteins, and modifications on PR gene transcription have been less characterized. These studies test the hypothesis that PR co-regulators alter PR-mediated transcriptional regulation in breast cancer cells. Herein, we establish how the interaction between PR/progesterone and prolactin, KDM4B, and O-GlcNAc modification via OGT alter the PR transcriptional landscape and oncogenic potential of breast cancer. We discovered that progesterone and prolactin modulate each other's transcription, and that this prolactin alteration to PR transcription was independent of the canonical prolactin signaling protein STAT5. We also established that knockdown of KDM4B does not significantly alter PR/progestin mediated gene programs. Finally, our lab has identified that PR interacts with OGT, leading to an O-GlcNAc post-translational modification on PR at residue Ser499. We also discovered that the combination of PR, progesterone, and increased levels of O-GlcNAc have an additive effect on tumor growth. It is significant that PR is capable of interacting with a multitude of co-regulators, and that these interactions lead to different effects of PR transcriptional regulation in breast cancer. These multiple co-regulators of PR complicate the study of PR in breast cancer but understanding these PR protein-protein interactions can help us better understand how PR targeted therapies would impact the transcriptional landscape and progression of tumors.

ISBN: 9798535575001Subjects--Topical Terms:

517296
Molecular biology.
Subjects--Index Terms:

Lysine demethylase 4B (KDM4B)

Protein Interactors Alter Progesterone Receptor (PR) Transcriptional Programs and Oncogenic Potential in Breast Cancer.
LDR:03769nmm a2200373 4500 001 2283663
005 20211115071525.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798535575001
035 $a (MiAaPQ)AAI28644924
035 $a AAI28644924
040 $a MiAaPQ $c MiAaPQ
100 1 $a Holloran, Sean Matthew. $0 (orcid)0000-0001-5094-0496 $3 3562669
245 1 0 $a Protein Interactors Alter Progesterone Receptor (PR) Transcriptional Programs and Oncogenic Potential in Breast Cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 126 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-03, Section: B.
500 $a Advisor: Hagan, Christy.
502 $a Thesis (Ph.D.)--University of Kansas, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Breast cancer is the second leading cause of cancer-related death among women in the United States. Upon diagnosis most breast cancers are diagnosed as hormone receptor (HR) positive. HR-positive tumors are classified by their expression of estrogen receptor (ER) and progesterone receptor (PR). ER signaling has been the primary focus of targeted therapies for HR-positive breast cancer. Standard of care for treatment of HR-positive breast cancer is to target ER/estrogen. Though these treatments have initial efficacy in most women with HR-positive breast cancer, many women will eventually relapse on these therapies. Thus, underscoring the clinical need for new, non-ER/estrogen-based treatments. The study of PR in breast cancer development and progression is not well understood. PR is a ligand-activated nuclear receptor that transcriptionally regulates a large repertoire of genes involved in cell cycle, growth, proliferation, and survival. PR/progesterone regulation has been well studied, but the impacts of other hormones, proteins, and modifications on PR gene transcription have been less characterized. These studies test the hypothesis that PR co-regulators alter PR-mediated transcriptional regulation in breast cancer cells. Herein, we establish how the interaction between PR/progesterone and prolactin, KDM4B, and O-GlcNAc modification via OGT alter the PR transcriptional landscape and oncogenic potential of breast cancer. We discovered that progesterone and prolactin modulate each other's transcription, and that this prolactin alteration to PR transcription was independent of the canonical prolactin signaling protein STAT5. We also established that knockdown of KDM4B does not significantly alter PR/progestin mediated gene programs. Finally, our lab has identified that PR interacts with OGT, leading to an O-GlcNAc post-translational modification on PR at residue Ser499. We also discovered that the combination of PR, progesterone, and increased levels of O-GlcNAc have an additive effect on tumor growth. It is significant that PR is capable of interacting with a multitude of co-regulators, and that these interactions lead to different effects of PR transcriptional regulation in breast cancer. These multiple co-regulators of PR complicate the study of PR in breast cancer but understanding these PR protein-protein interactions can help us better understand how PR targeted therapies would impact the transcriptional landscape and progression of tumors.
590 $a School code: 0099.
650 4 $a Molecular biology. $3 517296
650 4 $a DNA methylation. $3 3560639
650 4 $a Womens health. $3 3562508
650 4 $a Ontology. $3 530874
650 4 $a Cancer therapies. $3 3557730
650 4 $a Mammography. $3 832932
650 4 $a Pregnancy. $3 663805
650 4 $a Kinases. $3 3558077
650 4 $a Cell cycle. $3 766119
650 4 $a Breast cancer. $3 3543523
650 4 $a Statistical analysis. $3 3543751
650 4 $a Proteins. $3 558769
650 4 $a Hormone replacement therapy. $3 3562671
650 4 $a Hysterectomy. $3 3296701
650 4 $a Steroids. $3 697464
650 4 $a Ligands. $3 686413
650 4 $a Phosphorylation. $3 816803
650 4 $a Tumors. $3 893964
650 4 $a Breastfeeding & lactation. $3 3562672
650 4 $a Cell growth. $3 3560747
650 4 $a Biotechnology. $3 571461
650 4 $a Oncology. $3 751006
653 $a Lysine demethylase 4B (KDM4B)
653 $a O-GlcNAc transferase (OGT)
653 $a Progesterone
653 $a Progesterone receptor (PR)
653 $a Prolactin
653 $a Signal transducer and activator of transcription 5 (STAT5)
690 $a 0307
690 $a 0992
710 2 $a University of Kansas. $b Cancer Biology. $3 3562670
773 0 $t Dissertations Abstracts International $g 83-03B.
790 $a 0099
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28644924